February 2016

Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.

The development and approval of high-intensity focused ultrasound doesn’t qualify as moving at a glacial pace; if anything, it seems quite measured. In a crowded field of treatments, the technology is trying to gain a toehold.

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Clinical studies suggest that PARP inhibitors are highly efficacious in patients with metastatic castration-resistant prostate cancer with these alternations in DNA repair genes.